RedHill Biopharma Announces Acceptance of Oral Presentations on RHB-105 (H. pylori) and RHB-104 (Crohn’s Disease) Phase 3 Data at ACG 2019 Annual Scientific Meeting

    NEXT STORY
    Predictive Genetic Testing & Consumer/Wellness Genomics: World Market Anticipated to Witness a CAGR of 13.9% Over 2019-2025
    PREV STORY
    Sharps Compliance Reports Fiscal 2019 Fourth Quarter Results
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    PROTOKOLL FRÅN ÅRSSTÄMMA

    author_avatar
    NASDAQ Market News

    Clearside Biomedical Announces License Agreement with Aura Biosciences for Suprachoroidal Space Microinjector™ Designed to Optimize Ocular Oncology Drug Delivery

    author_avatar
    NASDAQ Market News

    Vectra® Study Published in the Journal Current Medical Research & Opinion

    author_avatar
    NASDAQ Market News